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Abstract. Alzheimer’s disease (AD) is the main neurodegenerative 
disorder worldwide. Its pathogenesis involves a network where 
various mechanisms are interconnected. This complex pathological 
network makes it extremely challenging to find an efficacious 
treatment. Herein, we give an overview on the design of the so-called 
multi-target-directed ligands, i.e. compounds that concurrently hit 
several key pathogenic factors within the network, as a realistic option 
to tackle AD, with a particular emphasis on some structural classes of 
multitarget hybrids recently developed in our group.              
 
Introduction 
       
      Alzheimer’s disease (AD) is characterized by an inexorable progressive 
deterioration in cognitive ability and capacity for independent living [1]. AD 
is the most prevalent neurodegenerative disorder and one of the most 
important health-care problems in developed countries. Over 47 million 
people live with dementia worldwide, and this number is estimated to increase 
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to more than 131 million by 2050, as populations age. Dementia also has a 
huge economic impact, with the total estimated worldwide cost being                
US $818 billion [2]. To aggravate this situation, current treatments against 
AD afford only temporary relief of the cognitive and functional symptoms, 
but do not prevent, halt, or delay disease progression. 
 During the past 40 years, intensive research efforts have aimed to 
decipher the mechanisms of AD progression. However, the etiology of AD is 
not yet completely understood, and the unique neuropathological clearly 
defined hallmarks are the senile plaques and neurofibrillary tangles (NFTs), 
which are mainly composed of aggregated β-amyloid peptide (Aβ) and 
hyperphosphorylated tau protein, respectively, together with a degeneration 
of the neurons and synapses [3,4]. The lack of success in discovering novel 
pharmaceuticals to tackle AD is very likely caused by the multifactorial 
nature of the disease, which involves various complex mechanisms where 
several key proteins and pathological pathways are interconnected in a 
robust network. Thus, we must conceive AD as a pathological network 
instead of a continuous process [5]. 
 Considering the mechanistic complexity involved in the pathological 
network of AD, it is easy to understand why the classic medicinal chemistry 
paradigm of developing drugs based on the reductionist approach of “one 
molecule-one target” has met with very limited success, which highlights the 
need for a more comprehensive pharmacological strategy to obtain effective 
outcomes. 
 In this context, some pharmacological approaches are available for the 
treatment of multifactorial diseases, such as AD. The most commonly used 
in general pharmacotherapy, referred to as multiple-medication therapy 
(MMT), consists of combining several drugs with different action 
mechanisms. However, this approach might imply patient compliance and 
pharmacokinetics issues [6,7]. An alternative approach relies on the use of a 
multiple-compound medication (MCM), which implies the incorporation of 
different drugs into the same formulation in order to simplify dosing 
regimens and improve patient compliance [6,7]. 
 Finally, a third strategy is based on the assumption that a single molecule 
may be able to hit multiple targets. This approach, the so-called multi-target-
directed ligand therapy (MTDL, Fig. 1), shows advantages over the 
aforementioned strategies, such as easier pharmacokinetics, improved efficacy 
due to synergistic effects, improved safety by preventing the risk of drug-drug 
interactions, and easier development, among others [6,8,9]. MTDLs can be 
rationally designed through the molecular assembly of distinct pharmacophore 
moieties of known bioactive molecules, where each drug entity has conserved 
the potential to interact with its specific site on the target [9]. 
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Figure 1. Different approaches to polypharmacological therapies against 
multifactorial diseases. Left: one-molecule-one-target strategy. Centre: multiple-
medication therapy (MMT); in case of multiple-compound medication (MCM), both 
drugs are applied in the same pill. Right: multi-target-directed ligand (MTDL) 
approach. 
 
 In this chapter, we briefly review the design of hybrid molecules with 
the aim of combating AD, either by increasing the potency against a specific 
target, or by using a MDTL strategy in order to concurrently affect several 
targets within the AD network. 
 
1. Increasing the potency against a key target, 
acetylcholinesterase 
 
 A common feature in AD patients is a cholinergic dysfunction, which 
is responsible for the clinical symptoms of the disease, which led to the 
postulation of the “cholinergic hypothesis of AD”. This hypothesis 
proposed that degeneration of cholinergic neurons and the associated loss 
of cholinergic neurotransmission contributed significantly to the 
deterioration in cognitive function, perception, comprehension, reasoning, 
and short-term memory, observed in patients with AD [10,11]. This 
abnormal acetylcholine (ACh) neurotransmission is caused by 
dysregulation at different levels of synapses, such as a decreased 
availability of ACh because of high-affinity choline uptake, reduced ACh 
release or reduced ACh synthesis [11,12]. 
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Figure 2. X-ray structure of hAChE (PDB ID: 3LII) with details of the CAS and the 
PAS. 
 
 At present, the most common therapeutic strategy aims at re-establishing 
the functional cholinergic neurotransmission by decreasing ACh metabolism 
through acetylcholinesterase inhibitors (AChEIs), which fit within the 
category of indirect cholinomimetic drugs [13]. Human AChE (hAChE) is 
the enzyme responsible for the hydrolysis of ACh, which takes place inside 
the catalytic anionic site (CAS) by means of the catalytic triad 
Ser203‐His447‐Glu334 (Fig. 2). A secondary binding site is the peripheral 
anionic site (PAS), which is located at the mouth of the narrow catalytic 
gorge and is responsible for the early binding and guiding of the substrate 
ACh towards the CAS [14,15]. 
 The “cholinergic hypothesis” has led to four out of the five marketed 
anti-Alzheimer drugs, which act as AChEIs and are only symptomatic and 
effective for a limited time. The first approved drug of this group was tacrine 
(1, Fig. 3) [16,17], although it was withdrawn from the market due to 
hepatotoxicity issues [18]. 
 
1.1. Huprines as a new class of highly potent AChEIs 
 
 An example of how the inhibitory activity against AChE can be greatly 
increased by achieving a larger number of interactions within the CAS of the 
enzyme was reported by the group of Camps and Muñoz-Torrero with the 
development of huprines, a new class of compounds that turned out to be 
among the most potent reversible AChEIs described so far [19-21]. Huprines 
were designed by a conjunctive approach, using as templates two well-known 
CAS inhibitors, namely (–)-huperzine A (2, Fig. 3), an alkaloid isolated from 
Huperzia serrata with potent AChE inhibitory activity that is commercialized  
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Figure 3. Design of huprines. 
 
as a nutraceutical in the USA [21], and tacrine (1). More than thirty different 
huprines were designed, synthesized and pharmacologically tested. The most 
active huprines prepared to date are the so-called (–)-huprine Y, (–)-3, and              
(–)-huprine X, (–)-4, which are, in racemic form, up to 640- and 810-fold more 
potent hAChE inhibitors than the parent compounds tacrine and (–)-huperzine 
A, respectively [21]. X-Ray diffraction studies confirmed the extended binding 
of huprines within the CAS of AChE as compared with the binding mode of 
their parent compounds, which accounts in a great part for the higher AChE 
inhibitory potency of huprines, thereby confirming the success of the 
hybridization strategy [22]. 
 
1.2 Benzonaphthyridine−tacrine hybrids as novel AChEIs 
 
 As a further step to increase AChE inhibitory activity by enlarging the 
number of interactions with the enzyme, the so-called dual site binding 
consists of the simultaneous interaction of a compound with the two terminal 
binding sites within the catalytic gorge of AChE, i.e. with the CAS and the 
PAS. An attractive example of rational design of a dual binding site AChEI 
with a dramatic improvement of inhibitory potency is the development of the 
benzonaphthyridine−tacrine hybrid 9 [23]. This hybrid compound features a 
tacrine-based CAS interacting unit linked, by means of a tether of suitable 
length, to a previously developed PAS interacting unit. 
Francisco Javier Pérez-Areales & Diego Muñoz-Torrero 48 
 Firstly, we carried out the design and synthesis of a PAS binding unit, 
structurally related to propidium (5, Fig. 4), a well-known PAS binding 
AChE inhibitor, which led to a pyrano[3,2-c]quinoline scaffold (6) [24]. 
Even though previous molecular dynamics (MD) simulations predicted that 
this structure would bind the PAS of AChE by means of π−π stacking 
interactions with residues Trp286 and Tyr72, compound 6 was found to be 
poorly active as AChEI (IC50 > 10 µM) [25]. Subsequent optimization of 
this PAS binding unit mainly involved the replacement of the oxygen atom 
at position 1 by a nitrogen. This structural modification should be 
accompanied by an increase in the basicity of the quinoline nitrogen atom, 
which, hence, should be protonated at physiological pH, thereby enabling 
additional cation−π interactions of the novel benzo[h][1,6]naphthyridine 
system (7, Fig. 4) at the PAS of AChE. MD simulations predicted an 
additional hydrogen bonding between the protonated pyridine nitrogen 
atom and the hydroxyl group of the PAS residue Tyr72 [26]. Compound 7 
turned out to be a potent PAS AChEI (IC50 = 65 nM), being 500-fold more 
potent than propidium and more than 150-fold more potent than the hit 6. 
 Afterwards, we developed a hybrid (9) that featured the PAS binding 
pharmacophore of 7 and a unit of the well-known CAS binding ligand           
6-chlorotacrine (8, an optimized derivative of tacrine, Fig. 5), a highly potent 
AChEI. Both moieties were connected through a 3-methylene linker, which 
was suggested by previous computational studies to be the most suitable to 
enable a dual site binding within AChE, thereby allowing the resulting 
hybrid to retain all the characteristic interactions of the parent compounds 
within the enzyme. Indeed, the 6-chlorotacrine fragment of the hybrid was 
predicted to be tightly bound at the CAS, with this moiety establishing 




Figure 4. Left: optimization process of PAS AChEIs. Right: representation of the 
binding mode of compound 7 at the PAS of AChE [26]. 
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Figure 5. Left: design of hybrid 9. Right: representation of the multi-site binding 
mode of hybrid 9 within AChE [23]. 
 
the protonated quinoline nitrogen with the carbonyl oxygen atom of His447. 
In turn, the benzo[h][1,6]naphthyridine moiety of the hybrid, whose 
quinoline nitrogen atom should be mostly protonated at physiological pH, 
was predicted to be firmly stacked against Trp286 at the PAS, establishing 
cation−π interactions. Remarkably, we found that an additional hydrogen 
bond could be formed between the amide group in the linker and Asp74. All 
this set of interactions along the catalytic gorge of AChE account for the 
extremely potent inhibitory activity of hybrid 9, beyond our expectations, in 
the low picomolar range (IC50 = 6 pM), with this compound being 1000-fold 
more potent than the reference compound 6-chlorotacrine (IC50 = 5.9 nM) 
[23]. 
 
2. Huprine-based MTDLs against AD 
 
 Senile plaques and NFTs, mainly composed of aggregated Aβ and 
hyperphosphorylated tau protein, respectively, constitute two 
histopathological hallmarks clearly defined in AD patients. Consequently, 
both events have brought about the pertinent hypotheses about the origin of 
AD pathology. Firstly, the “amyloid hypothesis” postulates that AD is 
caused by an imbalance between Aβ production and clearance, resulting in 
increased amounts of Aβ, whose accumulation and aggregation into 
oligomers, and eventually fibrils and plaques, leads to neuronal damage and 
cell death [27]. The central event in the amyloid hypothesis is an alteration 
in the metabolism of the amyloid precursor protein (APP), which is directed 
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to an amyloidogenic pathway in AD patients, by which the sequential 
cleavage of APP through β-secretase (BACE1) and γ-secretase, affords a     
39–43 amino acid polypeptide, Aβ, which is highly insoluble and shows 
strong tendency to aggregate [28]. In this regard, one of the most pursued 
targets in the search for new anti-Alzheimer drugs has been the modulation 
of Aβ production through BACE1 inhibitors [29]. BACE1 is an aspartic 
protease, whose active site contains two aspartate residues, Asp32 and 
Asp228, which are responsible for the initial cleavage of APP. The binding 
cleft is characterized for being partially covered by a highly flexible 
antiparallel hairpin-loop, referred to as the “flap”, which guides the entrance 
of the substrate into the catalytic site (Fig. 6) [30]. 
 On the other hand, the “tau hypothesis” postulates that AD patients 
suffer from an increased kinase activity, which triggers tau 
hyperphosphorylation, and detachment of the resulting distorted protein from 
the microtubules, so that the axon disintegrates and the skeleton of the 
neuron is no longer maintained. Without the cytoskeleton, neurons 
degenerate, and connections between neurons are lost, what eventually leads 
to apoptosis due to the loss of function [31,32]. Moreover, defective tau 
protein has a strong tendency to aggregate, forming paired helical filaments 
(PHF) inside the neuron, whose abnormal accumulation results in NFTs 
formation. Tau aggregation occurs through a nucleation-dependent 
elongation mechanism [33]. In fact, tau may adopt stable seed structures, 
displaying prion-like characteristics [34,35]. Therefore, prevention of tau 




Figure 6. Structure of BACE1 (PDB ID: 1SGZ) with the details of the catalytic 
anionic dyad and the “flap”. 
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2.1. Rhein−huprine hybrids as a new class of anti-Alzheimer MTDLs 
 
 The multifactorial nature of AD led to the establishment of the MTDL 
strategy as a promising, realistic therapeutic approach. In this context, 
rhein−huprine hybrids were designed as a novel structural family of MTDLs. 
This class of compounds had its origin in the finding that compounds sharing 
a core structure of hydroxyanthraquinone displayed tau anti-aggregating 
properties in vitro with IC50 values in the low micromolar range [36,37]. The 
structurally related compound rhein (10, Fig. 7, left) is a natural product 
found in the traditional Chinese herbal medicine rhubarb (Rheum rhabarbarum),  
which is well tolerated in humans [38]. We assumed that the 
hydroxyanthraquinone derivative rhein could also display tau anti-
aggregating activity. Accordingly, the first generation of rhein–huprine 
hybrids was designed by connecting the hydroxyanthraquinone system of 
rhein and a moiety of the potent AChEI huprine Y (3) with a linker of 
suitable length. The lead compound of this family turned out to be the 
nonamethylene-linked hybrid (±)-11 [39,40]. 
 This family of hybrids was endowed with a very interesting in vitro and 
in vivo multi-target profile, especially the lead compound (±)-11 (Fig. 7, 
right). Not unexpectedly, this compound displayed cholinergic activity 
through a potent inhibition of human AChE and butyrylcholinesterase 
(hBChE), and Aβ42 and tau anti-aggregating activity. But more surprisingly,  
                          
 
Figure 7. Left: rhein, 10, the lead compound of the first generation of rhein–huprine 
hybrids, (±)-11, and the p-phenylene-linked analog (±)-12. Right: multi-target 
biological profile of the lead compound (±)-11. 
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the lead compound (±)-11 was also found to be a potent inhibitor of 
hBACE1, which led to a significant Aβ lowering effect in a transgenic 
mouse model of AD (APP/PS1 mice) [39,40]. 
 To shed light on the binding mode within hAChE, molecular modeling 
studies were carried out for the p-phenylene-linked rhein–huprine hybrid 
(±)-12, a less flexible analog of (±)-11, which was still a potent hAChEI, 
with an IC50 value of 18 nM. These studies suggested that the potent 
inhibitory activity of these hybrids against hAChE arises from a dual site 
binding within the enzyme [40]. Likewise, a dual site binding was also 
predicted with regard to hBACE1 inhibition, with the huprine moiety 
interacting with the catalytic dyad and the rhein fragment interacting with an 
unexplored secondary binding site [40]. 
 Of note, the huprine moiety, protonated at physiological pH, remains 
tightly bound to the catalytic site in both hAChE and hBACE1 by means of 
hydrogen bonding interaction with His447 and cation–π interactions with 
Trp86 and Tyr337 at the CAS of AChE, and a salt bridge with the catalytic 
dyad of BACE1. The basicity of the huprine moiety of these hybrids is 
therefore crucial for AChE and BACE1 inhibition, due to the need of being 
protonated at physiological pH to enable these strong interactions [40]. 
 
2.2. Second generation rhein−huprine hybrids 
 
 In general, compounds with high basicity suffer from low brain 
exposure as a result of poor permeation through biological membranes, 
particularly the blood-brain barrier (BBB), and high P-glycoprotein (P-gp)-
mediated efflux liability [41,42]. Hence, tuning of drugs pKa has been an 
approach widely adopted to increase drug concentrations in brain [41,43]. In 
this light, a second generation of rhein−huprine hybrids was envisaged in 
order to explore how modulation of their basicity would affect their multiple 
biological activities, while trying to improve their pharmacokinetic 
properties. In the case of BACE1 inhibitors, the optimal balance between the 
relevant properties of enzymatic potency and pharmacokinetics has been 
reported for compounds with pKa values between 7 and 7.5 [44]. 
 For the design of the novel hybrids, the lead compound 11 was used as a 
template. Structural modification of its huprine moiety, i.e. the replacement 
of the chlorobenzene ring by other aromatic rings, should modify the 
basicity of the pyridine nitrogen. The selection of the novel huprines was 
made on the basis of their calculated pKa values by means of high-level 
quantum mechanical (QM) computations. In this way, we selected the              
1,4-difluorohuprine 13a (Fig. 8, left) and the thienohuprine 13b, with 
reduced basicity compared with huprine Y (pKa = 8.2, for the N-methylated  
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Figure 8. Left: selected modified huprines, (±)-13a-d, and their calculated pKa values 
determined for the N-methylated derivatives by QM computations. Right: novel 
rhein–huprine hybrids, (±)-14a-d. 
 
derivative of huprine Y), and the naphthyridine-based huprine 13c [45] and 
the methoxyhuprine 13d, which were predicted to be slightly more basic 
than huprine Y [46]. BACE1 localizes and is fully active in acidic 
endosomal compartments (pH 4.5–6.5) [47,48,49], where all the novel 
rhein–huprine hybrids, 14a-d (Fig. 8, right), should be mostly in protonated 
form and therefore able to form a salt bridge with the aspartate residues of 
the catalytic dyad. On the other hand, AChE is located at physiological pH in 
synapses, where the most basic hybrids 14c and 14d should be mostly 
protonated, thereby retaining their AChE inhibitory activity, while the least 
basic hybrids 14a and 14b should predominate in the neutral form, with the 
consequent loss of hydrogen bond and cation−π interactions at the CAS of 
AChE. 
 It has been previously reported that replacement of the chlorobenzene 
ring of huprines by other aromatic systems is detrimental for the AChE 
inhibitory activity [20,21,45]. In agreement with these previous findings, all 
novel hybrids were clearly less potent than the lead compound 11, but they 
still exhibited IC50 values in the submicromolar to low micromolar range, in 
most cases. As anticipated, the most potent second-generation hybrids were 
those of increased basicity, especially the naphthyridine derivative 14c                   
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(IC50 = 180 nM), since they should retain their ability to bind at the CAS of 
AChE. The lower inhibitory potency of hybrid 14c compared to the lead 11 
was studied by means of QM computations and showed unfavorable 
secondary interactions due to the electrostatic repulsion between the lone 
pairs of the nitrogen atom at position 1 and of the His447 carbonyl oxygen 
[46]. Moreover, the decreased activity of 14c might be ascribed to the 
absence of the chlorine atom present at position 3 of huprine Y, which fills a 
hydrophobic pocket near the CAS. 
 On the other hand, hybrids 14a and 14b displayed some hBACE1 
inhibitory activity (22% inhibition at 1 µM, and 34% inhibition at 80 nM, 
respectively), whereas compounds 14c and 14d turned out to be essentially 
inactive. Again, this series of compounds was clearly less potent than the lead 
11, despite the fact that all novel second-generation rhein–huprine hybrids 
should be protonated at the acidic pH in endosomal compartments where 
BACE1 is located. According to QM calculations, unfavorable electrostatic 
interactions of the thiophene derivative 14b with the carboxylate oxygens of 
the catalytic dyad of BACE1 might account for its lower potency compared 
with the lead compound 11 [46]. 
 Furthermore, this second generation of rhein–huprine hybrids retained 
the Aβ42 anti-aggregating activity, while displayed slightly increased tau 
anti-aggregating properties, compared with the lead compound 11.                   
A common feature of AD is the oxidative damage in cellular structures, 
which occurs after an overproduction of reactive oxygen species and a 
deficiency of the antioxidant systems. Thus, we also assessed the 
antioxidant capacity of this novel series of compounds because of the 
presence of phenolic groups in their structure, and since it had been 
previously reported that rhein as well as huprine Y and a class of           
huprine-based hybrids were endowed with antioxidant properties 
[50,51,52]. Very interestingly, all the novel hybrids turned out to be potent 
antioxidant agents, being 10–22-fold and 12–13-fold more potent than 
trolox in the ABTS˙
+
 and DPPH assays, respectively, and slightly more 
potent than gallic acid [46]. Interestingly, using the PAMPA-BBB assay, 
all the hybrids were predicted to have good BBB permeability, a necessary 




 Novel approaches have to be explored to identify drugs that can 
efficiently treat AD. Focusing on the symptomatic treatment of AD by 
means of cholinomimetic agents, we have shown that molecular 
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hybridization is an effective strategy to derive extremely potent 
(subnanomolar or picomolar) AChEIs that display a wide array of 
interactions either at the CAS of the enzyme (e.g. huprines) or in a dual site 
manner, from the CAS to the PAS, all along the AChE catalytic gorge (e.g. 
benzonaphthyridine-chlorotacrine hybrids). More interestingly, molecular 
hybridization is an essential tool to design MTDLs, in a very promising 
approach to derive new drugs that are able to confront the complex 
pathological network of AD, and, hence, to modify the natural course of this 
devastating disease. Results from preclinical studies with animal models of 
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